Since CTCL is characterized by long-lasting course and rather rare aggressive progression, it is interesting whether the variability of IL-6 and STAT3 genes is associated with the course of disease. The gene discussed is STAT3; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.